Mesothelioma
Conditions
Keywords
Immunotoxin, Mesothelin, Targeted Therapy
Brief summary
Background: LMB-100 is a man-made protein. It is attracted to the mesothelin protein. This is found in many tumors, including mesothelioma. But it is found in only a very small number of normal tissues. After binding to mesothelin on tumors, LMB-100 attacks and kills cancer cells. Researchers want to test LMB-100 in people with advanced mesothelioma. Objective: To find a safe dose and anti-tumor activity of LMB-100 for people with advanced mesothelioma. Eligibility: Adults ages 18 and older with: Advanced pleural or peritoneal mesothelioma that has not responded to platinum-based therapy Adequate organ function Design: Participants will be screened with: Samples of tumor tissue or tumor fluid. These can be new or from a previous procedure. Medical history Physical exam Blood, urine, and heart tests Chest x-rays Computed tomography (CT) or magnetic resonance imaging (MRI) scans Fluorodeoxyglucose (FDG)-positron emission tomography (PET) scans Participants will get LMB-100 on days 1, 3, and 5 of each 21-day cycle. It will be given through an intravenous (IV) catheter, a tube inserted in an arm vein. They will get standard medicines before each infusion to help prevent side effects. Each infusion lasts about 30 minutes. They will be monitored for up to 2 hours after. During each cycle, participants will repeat the screening tests. Participants will get the study drug for up to 4 cycles or until their disease worsens or they have intolerable side effects. About 4-6 weeks after their last infusion, participants will have a follow-up visit. They will repeat the study tests. Participants will have follow-up scans every 6 weeks until their disease gets worse. Participants will be called about once a year to see how they are doing.
Detailed description
Background: * Although mesothelioma patients with a limited tumor burden may benefit from surgical resection, most patients have advanced disease at diagnosis and are not candidates for cytoreductive surgery. * For mesothelioma patients who are not eligible for curative surgery, the median survival with supportive care alone is 6 months whereas with the current standard treatment, a combination of cisplatin and pemetrexed, the median survival is 12 months. * Mesothelin, a tumor differentiation antigen, is expressed in over 95% of epitheloid mesothelioma. Mesothelin is a suitable candidate for targeted therapy due to its very limited expression in normal human tissue and its high expression in several tumors including mesothelioma. * LMB-100 is a novel recombinant anti-mesothelin immunotoxin developed for the treatment of patients with solid tumors that express mesothelin. Mesothelin is targeted by linking a humanized fragment of the anti-mesothelin Fab to a de-immunized Pseudomonas exotoxin (PE). * The clinical use of first generation immunotoxins such as SS1P was hampered mainly by their high immunogenicity. LMB-100 is a next generation PE-fusion protein that has been protein-engineered to maximally reduce its immunogenicity. LMB-100 has shown broad activity against different mesothelin expressing cancer cell lines and tumor xenograft models. Objectives: Phase 1 To identify the recommended phase 2 dose (RP2D) of LMB-100 in patients with treatment refractory advanced epithelioid or biphasic mesothelioma and evaluate potential efficacy of the identified RP2D. -Phase 2 To determine the efficacy of LMB-100 with respect to objective response rate in patients with treatment refractory advanced epithelioid or biphasic mesothelioma. Eligibility: * Age greater than or equal to 18 years * Histologically confirmed advanced pleural or peritoneal mesothelioma * Subjects must have had at least 1 prior chemotherapy regimen with last dose of previous therapy occurring at 3 weeks before the start of study treatment * Adequate organ function * Participants with central nervous system (CNS) metastases or prior pneumonectomy are excluded Design: * This is a Phase I, open-label study to evaluate the safety, pharmacokinetics, and activity of LMB-100 in patients with treatment refractory advanced epithelioid or biphasic mesothelioma. * LMB-100 will be administered intravenously on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles * Tumor response will be assessed after every 2 cycles * Optional tumor biopsies may be collected at baseline and after 2 cycles of therapy * The accrual ceiling will be set at 30
Interventions
DRUGLMB-100
Administered intravenous (IV) on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles (Arms A1 and A2) or 2 cycles (Arms B1 and B2)
DRUGnab-paclitaxel
Arms B1 and B2 only. Administered intravenous (IV) on days 1 and 8 of each 21 day cycle for up to 6 cycles
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* INCLUSION CRITERIA (All Cohorts): * Histologically confirmed epithelial or biphasic mesothelioma not amenable to potentially curative surgical resection. However, patients with biphasic tumors that have a more than or equal to 50% sarcomatoid component will be excluded. The diagnosis will be confirmed by the Laboratory of Pathology, Center for Cancer Research (CCR), National Cancer Institute (NCI). * Archival sample or fresh biopsy or tumor effusion must be available for confirmation of diagnosis. * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as greater than or equal to 20 mm with conventional techniques or as greater than or equal to10 mm with spiral computed tomography (CT) scan. * Patients must have had at least one prior chemotherapy regimen that includes pemetrexed and cisplatin or carboplatin. There is no limit to the number of prior chemotherapy regimens received. * The last dose of previous therapy must have occurred at least 3 weeks prior to the start of study therapy. Palliative radiotherapy is allowed up to 2 weeks before the first LMB-100 infusion. * Patients for whom no standard curable therapy exists * Age greater than or equal to 18 years. Because no dosing or adverse event data are currently available on the use of LMB-100 in patients \<18 years of age, children are excluded from this study * All acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure must have resolved to Grade less than or equal to 1, except alopecia (any grade) and Grade 2 peripheral neuropathy. * Eastern Cooperative Oncology (ECOG) performance status (PS) 0 or1 * Adequate hematological function: neutrophil count of more than of equal to 1.5x10\^9 cells/L, platelet count of greater than or equal to 100,000/microl, (transfusion independent, defined as not receiving platelet transfusions within 7 days prior to laboratory sample) hemoglobin more than or equal to 9 g/dL * Adequate Liver function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 2.5 X upper limit of normal alkaline phosphate less than 2.5 X upper limit of normal unless bone metastasis is present (less than 5 X upper limit of normal) in the absence of liver metastasis. * Bilirubin less than or equal to 1.5 mg/dL (excluding Gilbert's Syndrome, see below). * Patients with Gilbert's syndrome will be eligible for the study. The diagnosis of Gilbert's syndrome is suspected in people who have persistent, slightly elevated levels of unconjugated bilirubin without any other apparent cause. A diagnosis of Gilbert's syndrome will be based on the exclusion of other diseases based on the following criteria: * Unconjugated hyperbilirubinemia noted on several occasions * No evidence of hemolysis (normal hemoglobin, reticulocyte count, and lactate dehydrogenase (LDH) * Normal liver function tests * Absence of other diseases associated with unconjugated hyperbilirubinemia * Adequate renal function: creatinine less than 1.5 mg/dL OR creatinine clearance (by Cockcroft Gault formula) greater than or equal to 50 mL/min. * Must have serum albumin \> 2.5 mg/dL without intravenous supplementation * Must have left ventricular ejection fraction \> 50% * Must have an ambulatory oxygen saturation of \> 90% on room air * Women of child-bearing potential (defined as a sexually mature woman who (1) has not undergone hysterectomy \[the surgical removal of the uterus\] or bilateral oophorectomy \[the surgical removal of both ovaries\] or; (2) has not been naturally postmenopausal for at least 24 consecutive months \[i.e., has had menses at any time during the preceding 24 consecutive months\]) must: * Either commit to true abstinence\* from heterosexual contact (which must be reviewed on a monthly basis), or agree to use, and be able to comply with, effective contraception without interruption, 28 days prior to starting study therapy (including dose interruptions), while on study medication and for 3 months after the last dose of study therapy; and * Have a negative serum pregnancy test (\<= -human chorionic gonadotropin (hCG) result at screening and agree to ongoing pregnancy testing during the course of the study, and after the end of study therapy. This applies even if the subject practices true abstinence\* from heterosexual contact. * Men must agree to practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 6 months following discontinuation of study therapy, even if he has undergone a successful vasectomy. * Ability of subject to understand and the willingness to sign a written informed consent document.
Exclusion criteria
(All Cohorts): -Known or clinically suspected central nervous system (CNS) primary tumors or metastases including leptomeningeal metastases. History or clinical evidence of CNS metastases unless they have been previously treated, are asymptomatic, and have had no requirement for steroids or enzyme-inducing anticonvulsants in the last 14 days. Evidence of significant, uncontrolled concomitant diseases which could affect compliance with the protocol or interpretation of results, including significant pulmonary disease other than primary cancer, uncontrolled diabetes mellitus, and/or significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, unstable angina, or clinically significant pericardial effusion) * Active or uncontrolled infections. * Human immunodeficiency virus (HIV) or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. HIV positive patients will be excluded due to a theoretical concern that the degree of immune suppression associated with the treatment may result in progression of HIV infection. * Patients with prior pneumonectomy * Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug * Major surgery or significant traumatic injury greater than or equal to 28 days prior to the first LMB-100 infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment * Dementia or altered mental status that would prohibit informed consent * Live attenuated vaccinations 14 days prior to treatment * Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with LMB-100, breastfeeding should be discontinued if the mother is treated with LMB-100. These potential risks may also apply to other agents used in this study. * Known hypersensitivity to any of the components of LMB-100 * High doses of systemic corticosteroids within 7 days prior to first dosing. High dose is considered as \> 20 mg of dexamethasone a day (or equivalent) for \> 7 consecutive days.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recommended Phase 2 Dose (RP2D) of LMB100 + Nab-paclitaxel | 3 weeks after initial dose | Highest administered dose of LMB-100 + nab-paclitaxel at which no more than 1 of 6 participants experiences a dose limiting toxicity (DLT). A DLT is any of the following events attributed to LMB-100 and occurring within 21 days after the first dose of LMB-100 such as Grade 4 neutropenia, Grade 3 and 4 febrile neutropenia, Grade 4 thrombocytopenia, Grade 3 thrombocytopenia associated with bleeding episodes. Grade ≥ 3 non-hematological toxicity with the exception of alopecia (any grade), Grade 3 nausea and vomiting without appropriate treatment, Grade 3 diarrhea lasting for ≤ 2 days with no fever or dehydration. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants at Recommended Phase 2 Dose (RP2D) With Partial or Complete Response by the Response Evaluation Criteria in Solid Tumors (RECIST) | End of treatment, an average of 57.6 days | Number of participants at maximum tolerated dose (MTD) with partial or complete response measured by the Response Evaluation Criteria in Solid Tumors (RECIST). Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Complete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. |
| Median Progression Free Survival (PFS) | At progression, up to 3.6 months | PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Progression was measured by the Response Evaluation Criteria in Solid Tumors (RECIST). Progression is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progressions. |
| Median Overall Survival (OS) | At death, up to 60.8 months | OS is defined as the duration of time from start of treatment to time of death. |
| Number of Participants With LMB-100 Maximum Observed Serum Concentration (Cmax) of >100ng/mL | Cycle 1 and Cycle 2 (each cycle is 21 days), approximately 42 days | Number of participants with LMB-100 Maximum observed serum concentration (Cmax) of \>100ng/mL was measured by |
| Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | 30 days after treatment | Adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). Grade 3 is serious, Grade 4 is life-threatening, and Grade 5 is death related to adverse event. |
| Duration of Response (DOR) | time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented by computed tomography (CT) scans performed every 6 weeks. | The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Progressive disease was measured by the Response Evaluation Criteria in Solid Tumors (RECIST) and is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progressions. |
| Number of Participants With Anti-drug Antibodies (ADAs) Formation to LMB-100 | Cycle 1 and Cycle 2 (each cycle is 21 days), approximately 42 days | ADAs formation to LMB-100 were measured by the enzyme-linked immunosorbent assay (ELISA). The presence of ADAs (i.e., positive) may indicate the participant may have poor blood levels. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). | Date treatment consent signed to date off study, approximately 34 months and 19 days for Dose Level 1, 52 months for Dose Level -1, and 42 months and 3 days for Dose Level -2. | Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. |
| Number of Participants With Dose-limiting Toxicities (DLT) | First 21 days after first dose of LMB-100 | A DLT is any of the following events attributed to LMB-100 and occurring within 21 days after the first dose of LMB-100 such as Grade 4 neutropenia, Grade 3 and 4 febrile neutropenia, Grade 4 thrombocytopenia, Grade 3 thrombocytopenia associated with bleeding episodes. Grade ≥ 3 non-hematological toxicity with the exception of alopecia (any grade), Grade 3 nausea and vomiting without appropriate treatment, Grade 3 diarrhea lasting for ≤ 2 days with no fever or dehydration. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Dose Level 1: 170mcg LMB-100 Dose Level 1: 170mcg LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles. | 3 |
| Dose Level -1: 140mcg LMB-100 Dose Level -1: 140mcg LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles. | 7 |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel given intravenously. LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 2 cycles. Nab-Paclitaxel given intravenously on days 1 and 8 of each 21 day cycle for up to 6 cycles. | 11 |
| Total | 21 |
Baseline characteristics
| Characteristic | Dose Level 1: 170mcg LMB-100 | Dose Level -1: 140mcg LMB-100 | Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 2 Participants | 3 Participants | 1 Participants | 6 Participants |
| Age, Categorical Between 18 and 65 years | 1 Participants | 4 Participants | 10 Participants | 15 Participants |
| Age, Continuous | 58.77 years STANDARD_DEVIATION 19.07 | 57.09 years STANDARD_DEVIATION 11.84 | 52.45 years STANDARD_DEVIATION 16.46 | 54.9 years STANDARD_DEVIATION 14.87 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants | 7 Participants | 10 Participants | 20 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 1 Participants | 2 Participants |
| Race (NIH/OMB) White | 3 Participants | 6 Participants | 8 Participants | 17 Participants |
| Region of Enrollment United States | 3 participants | 7 participants | 11 participants | 21 participants |
| Sex: Female, Male Female | 1 Participants | 5 Participants | 6 Participants | 12 Participants |
| Sex: Female, Male Male | 2 Participants | 2 Participants | 5 Participants | 9 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 3 / 3 | 6 / 7 | 11 / 11 |
| other Total, other adverse events | 3 / 3 | 7 / 7 | 11 / 11 |
| serious Total, serious adverse events | 1 / 3 | 0 / 7 | 4 / 11 |
Outcome results
Primary
Recommended Phase 2 Dose (RP2D) of LMB100 + Nab-paclitaxel
Highest administered dose of LMB-100 + nab-paclitaxel at which no more than 1 of 6 participants experiences a dose limiting toxicity (DLT). A DLT is any of the following events attributed to LMB-100 and occurring within 21 days after the first dose of LMB-100 such as Grade 4 neutropenia, Grade 3 and 4 febrile neutropenia, Grade 4 thrombocytopenia, Grade 3 thrombocytopenia associated with bleeding episodes. Grade ≥ 3 non-hematological toxicity with the exception of alopecia (any grade), Grade 3 nausea and vomiting without appropriate treatment, Grade 3 diarrhea lasting for ≤ 2 days with no fever or dehydration.
Time frame: 3 weeks after initial dose
Population: Number of participants in the recommended Phase 2 (RP2D) of LMB-100 and the recommended Phase 2 Dose (RP2D) of LMB100 + Nab-paclitaxel are noted below.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| All Participants | Recommended Phase 2 Dose (RP2D) of LMB100 + Nab-paclitaxel | Recommended Phase 2 (RP2D) of LMB-100 | 140 mcg |
| All Participants | Recommended Phase 2 Dose (RP2D) of LMB100 + Nab-paclitaxel | Recommended Phase 2 Dose (RP2D) of LMB100 + Nab-paclitaxel | 100 mcg |
Secondary
Duration of Response (DOR)
The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Progressive disease was measured by the Response Evaluation Criteria in Solid Tumors (RECIST) and is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progressions.
Time frame: time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented by computed tomography (CT) scans performed every 6 weeks.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| All Participants | Duration of Response (DOR) | NA months |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Duration of Response (DOR) | NA months |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Duration of Response (DOR) | NA months |
Secondary
Median Overall Survival (OS)
OS is defined as the duration of time from start of treatment to time of death.
Time frame: At death, up to 60.8 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| All Participants | Median Overall Survival (OS) | 33.5 months |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Median Overall Survival (OS) | 16.9 months |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Median Overall Survival (OS) | 10.1 months |
Secondary
Median Progression Free Survival (PFS)
PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Progression was measured by the Response Evaluation Criteria in Solid Tumors (RECIST). Progression is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progressions.
Time frame: At progression, up to 3.6 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| All Participants | Median Progression Free Survival (PFS) | 2.7 months |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Median Progression Free Survival (PFS) | 2.7 months |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Median Progression Free Survival (PFS) | 2.7 months |
Secondary
Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel
Adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). Grade 3 is serious, Grade 4 is life-threatening, and Grade 5 is death related to adverse event.
Time frame: 30 days after treatment
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| All Participants | Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | Grade 3 hypotension probably related | 0 adverse events |
| All Participants | Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | Grade 3 hyponatremia possibly related | 0 adverse events |
| All Participants | Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | Grade 3 CPK increased probably related | 0 adverse events |
| All Participants | Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | Grade 4 CPK increased probably related | 0 adverse events |
| All Participants | Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | Grade 3 edema limbs possibly related | 0 adverse events |
| All Participants | Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | Grade 3 atrial fibrillation probably related | 0 adverse events |
| All Participants | Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | Grade 3 hyponatremia definitely related | 0 adverse events |
| All Participants | Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | Grade 3 hypoalbuminemia definitely related | 0 adverse events |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | Grade 3 edema limbs possibly related | 0 adverse events |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | Grade 3 hypoalbuminemia definitely related | 0 adverse events |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | Grade 3 hyponatremia possibly related | 0 adverse events |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | Grade 3 hyponatremia definitely related | 2 adverse events |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | Grade 4 CPK increased probably related | 0 adverse events |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | Grade 3 hypotension probably related | 0 adverse events |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | Grade 3 CPK increased probably related | 0 adverse events |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | Grade 3 atrial fibrillation probably related | 0 adverse events |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | Grade 3 CPK increased probably related | 1 adverse events |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | Grade 3 hyponatremia possibly related | 1 adverse events |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | Grade 3 edema limbs possibly related | 1 adverse events |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | Grade 3 hypotension probably related | 1 adverse events |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | Grade 4 CPK increased probably related | 1 adverse events |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | Grade 3 atrial fibrillation probably related | 1 adverse events |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | Grade 3 hypoalbuminemia definitely related | 4 adverse events |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Grade 3-5 Adverse Events Possibly, Probably, and/or Definitely Related to the LMB-100 +/- Nab-Paclitaxel | Grade 3 hyponatremia definitely related | 0 adverse events |
Secondary
Number of Participants at Recommended Phase 2 Dose (RP2D) With Partial or Complete Response by the Response Evaluation Criteria in Solid Tumors (RECIST)
Number of participants at maximum tolerated dose (MTD) with partial or complete response measured by the Response Evaluation Criteria in Solid Tumors (RECIST). Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Complete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm.
Time frame: End of treatment, an average of 57.6 days
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| All Participants | Number of Participants at Recommended Phase 2 Dose (RP2D) With Partial or Complete Response by the Response Evaluation Criteria in Solid Tumors (RECIST) | Complete Response | 0 Participants |
| All Participants | Number of Participants at Recommended Phase 2 Dose (RP2D) With Partial or Complete Response by the Response Evaluation Criteria in Solid Tumors (RECIST) | Partial Response | 0 Participants |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Participants at Recommended Phase 2 Dose (RP2D) With Partial or Complete Response by the Response Evaluation Criteria in Solid Tumors (RECIST) | Complete Response | 0 Participants |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Participants at Recommended Phase 2 Dose (RP2D) With Partial or Complete Response by the Response Evaluation Criteria in Solid Tumors (RECIST) | Partial Response | 0 Participants |
Secondary
Number of Participants With Anti-drug Antibodies (ADAs) Formation to LMB-100
ADAs formation to LMB-100 were measured by the enzyme-linked immunosorbent assay (ELISA). The presence of ADAs (i.e., positive) may indicate the participant may have poor blood levels.
Time frame: Cycle 1 and Cycle 2 (each cycle is 21 days), approximately 42 days
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| All Participants | Number of Participants With Anti-drug Antibodies (ADAs) Formation to LMB-100 | Cycle 2 | 3 Participants |
| All Participants | Number of Participants With Anti-drug Antibodies (ADAs) Formation to LMB-100 | Cycle 1 | 0 Participants |
| All Participants | Number of Participants With Anti-drug Antibodies (ADAs) Formation to LMB-100 | No ADA formation | 0 Participants |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Participants With Anti-drug Antibodies (ADAs) Formation to LMB-100 | Cycle 2 | 5 Participants |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Participants With Anti-drug Antibodies (ADAs) Formation to LMB-100 | Cycle 1 | 2 Participants |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Participants With Anti-drug Antibodies (ADAs) Formation to LMB-100 | No ADA formation | 0 Participants |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Participants With Anti-drug Antibodies (ADAs) Formation to LMB-100 | Cycle 1 | 3 Participants |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Participants With Anti-drug Antibodies (ADAs) Formation to LMB-100 | No ADA formation | 2 Participants |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Participants With Anti-drug Antibodies (ADAs) Formation to LMB-100 | Cycle 2 | 5 Participants |
Secondary
Number of Participants With LMB-100 Maximum Observed Serum Concentration (Cmax) of >100ng/mL
Number of participants with LMB-100 Maximum observed serum concentration (Cmax) of \>100ng/mL was measured by
Time frame: Cycle 1 and Cycle 2 (each cycle is 21 days), approximately 42 days
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| All Participants | Number of Participants With LMB-100 Maximum Observed Serum Concentration (Cmax) of >100ng/mL | Cycle 1 | 3 Participants |
| All Participants | Number of Participants With LMB-100 Maximum Observed Serum Concentration (Cmax) of >100ng/mL | Cycle 2 | 2 Participants |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Participants With LMB-100 Maximum Observed Serum Concentration (Cmax) of >100ng/mL | Cycle 1 | 7 Participants |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Participants With LMB-100 Maximum Observed Serum Concentration (Cmax) of >100ng/mL | Cycle 2 | 4 Participants |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Participants With LMB-100 Maximum Observed Serum Concentration (Cmax) of >100ng/mL | Cycle 1 | 10 Participants |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Participants With LMB-100 Maximum Observed Serum Concentration (Cmax) of >100ng/mL | Cycle 2 | 3 Participants |
Other Pre-specified
Number of Participants With Dose-limiting Toxicities (DLT)
A DLT is any of the following events attributed to LMB-100 and occurring within 21 days after the first dose of LMB-100 such as Grade 4 neutropenia, Grade 3 and 4 febrile neutropenia, Grade 4 thrombocytopenia, Grade 3 thrombocytopenia associated with bleeding episodes. Grade ≥ 3 non-hematological toxicity with the exception of alopecia (any grade), Grade 3 nausea and vomiting without appropriate treatment, Grade 3 diarrhea lasting for ≤ 2 days with no fever or dehydration.
Time frame: First 21 days after first dose of LMB-100
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| All Participants | Number of Participants With Dose-limiting Toxicities (DLT) | 0 Participants |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Participants With Dose-limiting Toxicities (DLT) | 0 Participants |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Participants With Dose-limiting Toxicities (DLT) | 1 Participants |
Other Pre-specified
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0).
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
Time frame: Date treatment consent signed to date off study, approximately 34 months and 19 days for Dose Level 1, 52 months for Dose Level -1, and 42 months and 3 days for Dose Level -2.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| All Participants | Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). | 3 Participants |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). | 7 Participants |
| Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel | Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). | 11 Participants |